Vaxcyte, Inc.
PCVX
$33.02
-$0.93-2.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.24% | 62.93% | 47.31% | 48.55% | 51.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.94% | -17.55% | 23.80% | 75.54% | 60.79% |
| Operating Income | -57.94% | 17.55% | -23.80% | -75.54% | -60.79% |
| Income Before Tax | -48.09% | 24.18% | -11.29% | -88.33% | -57.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.09% | 24.18% | -11.29% | -88.33% | -57.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.09% | 24.18% | -11.29% | -88.33% | -57.16% |
| EBIT | -57.94% | 17.55% | -23.80% | -75.54% | -60.79% |
| EBITDA | -56.72% | 18.63% | -23.09% | -75.50% | -61.00% |
| EPS Basic | -21.90% | 42.50% | 8.53% | -57.50% | -21.29% |
| Normalized Basic EPS | -21.91% | 42.52% | 8.51% | -57.53% | -21.31% |
| EPS Diluted | -21.90% | 42.50% | 8.53% | -57.50% | -21.29% |
| Normalized Diluted EPS | -21.91% | 42.52% | 8.51% | -57.53% | -21.31% |
| Average Basic Shares Outstanding | 21.49% | 31.87% | 21.66% | 19.58% | 29.56% |
| Average Diluted Shares Outstanding | 21.49% | 31.87% | 21.66% | 19.58% | 29.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |